Skip to content

Depression: all studies

Page 221 of 1,034: studies 2,201 to 2,210 of 10,336, newest first. Back to the depression overview

Research

A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings.

Journal of Affective Disorders 2022 L. Mcinnes, Jimmy J Qian, Rishab Gargeya et al. 60 citations

BACKGROUND Outcomes of ketamine intravenous therapy (KIT) for depression in real-world care settings have been minimally evaluated. We set out to quantify treatment response to KIT in a large sample of patients from community-based practices. METHODS We retrospectively analyzed 9016 depression patients who received KIT between 2016 and 2020 at one of 178 community practices across the United...

Glutamatergic receptor and neuroplasticity in depression: Implications for ketamine and rapastinel as the rapid-acting antidepressants.

Biochemical and Biophysical Research Communications 2022 Ya-Ting Wang, Ning-Ning Zhang, Ling Liu et al. 47 citations

PURPOSE OF REVIEW To explore the convergent downstream pathways of ketamine and rapastinel and drive further development of identification for following generational rapid-acting antidepressants in the synaptic process. RECENT FINDINGS Ketamine is an NMDAR antagonist and is proven effective in depression for the rapid and sustained antidepressant response, while rapastinel is an NMDAR positive...

Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence.

Journal of Neurological Sciences 2022 Subha Subramanian, S. Haroutounian, Ben J Palanca et al. 58 citations

Ketamine is an anesthetic drug which is now used to treat chronic pain conditions and psychiatric disorders, especially depression. It is an N-methyl-D-aspartate (NMDA) receptor antagonist with additional effects on α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, opioid receptors, and monoaminergic...

Med Check: Aduhelm and Alzheimer's; BNC210 and Social Anxiety Disorder; COMP360 Psilocybin, Depression and More

Psychiatric News 2022 T. D'Arrigo

Aduhelm Shows Promise for Alzheimer's DiseaseTwo phase 3 clinical trials of Aduhelm (aducanumab) showed a correlation between plasma p-tau reduction and less cognitive and functional decline in patients with Alzheimer's disease, Biogen and Esai announced last November. The accumulation of the protein tau inside neurons leads to neurofibrillary tangles—a pathological hallmark of Alzheimer's...

Ketamine abrogates sensorimotor deficits and cytokine dysregulation in a chronic unpredictable mild stress model of depression.

Psychopharmacology 2022 Edem Ekpenyong Edem, Collins-Kevin Chukwudi Anyanwu, Kate Eberechukwu Nebo et al. 9 citations

Major depressive disorder (MDD) is a serious mental disorder with influence across the functional systems of the body. The pathogenesis of MDD has been known to involve the alteration of normal body functions responsible for the normal inflammation processes within the CNS; this along with other effects results in the depreciation of the sensorimotor performance of the body. Ketamine...

Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence.

Psychiatry Research 2022 Joshua D. Di Vincenzo, Orly Lipsitz, Nelson B Rodrigues et al. 11 citations

Antidepressants are associated with symptomatic worsening in a subgroup of patients. Replicated evidence has demonstrated rapid and robust antidepressant effects with intravenous (IV) ketamine in treatment resistant depression (TRD); however, the risk of ketamine worsening depressive symptoms in a subgroup of patients remains unknown. Herein we report a retrospective analysis on the rates of...

Low-dose S-ketamine exerts antidepressant-like effects via enhanced hippocampal synaptic plasticity in postpartum depression rats.

Neurobiology of Stress 2022 Zhuoyu Ren, Mingling Wang, Mokhtar Aldhabi et al. 28 citations

Rapid antidepressant effects of S-ketamine have repeatedly been confirmed in patients with depression, as well as in chronic unpredictable mild stress (CUMS) animal models. However, the pharmacological study of S-ketamine for anti-postpartum depression has not been considered. In this study, the classical method of reproductive hormone withdrawal was used to construct a rat model of postpartum...

Intravenous ketamine for depression: A clinical discussion reconsidering best practices in acute hypertension management.

Frontiers in Psychiatry 2022 Ryan Yip, Jennifer Swainson, Atul Khullar et al. 13 citations

Ketamine is a versatile medication with an emerging role for the treatment of numerous psychiatric conditions, including treatment resistant depression. Current psychiatry guidelines for its intravenous administration to treat depression recommend regular blood pressure monitoring and an aggressive approach to potential transient hypertensive episodes induced by ketamine infusions. While this...

DOI: 10.3389/fpsyt.2022.1017504 (opens in new tab) Full text (opens in new tab) Hypertension Hypertensive emergency Ketamine infusion Treatment resistant depression

Antidepressant Effect of Ketamine on Inflammation‐Mediated Cytokine Dysregulation in Adults with Treatment‐Resistant Depression: Rapid Systematic Review

Oxidative Medicine and Cellular Longevity 2022 Shiryn D. Sukhram, Grozdena Yilmaz, Jianying Gu 26 citations

Background . Major depressive disorder (MDD) and treatment‐resistant depression (TRD) represent a global source of societal and health burden. To advise proper management of inflammation‐related depression among TRD patients, it is important to identify therapeutic clinical treatments. A key factor is related to proinflammatory cytokines such as interleukin‐ (IL‐) 1 β , IL‐6, and tumor necrosis...

Ayahuasca for the Treatment of Depression.

Current Topics in Behavioral Neurosciences 2022 Fernanda Palhano-Fontes, Bruno Lobão‐soares, Nicole Leite Galvão‐coelho et al. 25 citations

Ayahuasca, the vine of the souls in Quechua, is a psychedelic brew with a few formulations that most often include the bark of a liana in the Malpighiaceae family (Banisteriopsis caapi), with leaves from a shrub in the coffee family Rubiaceae (Psychotria viridis). Mixed with water and boiled for hours or days, it produces a brownish-colored liquid with a strong and characteristic taste....